| P50 | author | Guillermo Quindós Andrés | Q43182008 |
| P2093 | author name string | Carmen Rubio | |
| | Julian Torre-Cisneros | |
| | Estrella Martín-Mazuelos | |
| | Enric Carreras | |
| | José Miguel Cisneros | |
| | Carlos Lumbreras | |
| | Francisco Álvarez-Lerma | |
| | Guillermo Quindos | |
| | Javier Peman | |
| | José Garnacho | |
| | Juan Luis Rodríguez Tudela | |
| P2860 | cites work | Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay | Q46503389 |
| | Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program | Q46663951 |
| | Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome | Q46758158 |
| | Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. | Q50700185 |
| | Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. | Q51192827 |
| | Risk Factors for Invasive Aspergillosis in Solid-Organ Transplant Recipients: A Case-Control Study | Q57569335 |
| | European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region | Q59400777 |
| | Preemptive Therapy in Immunocompromised Hosts | Q67914367 |
| | Detection of Aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study | Q80008313 |
| | Invasive aspergillosis in critically ill patients without malignancy | Q80269940 |
| | Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance | Q80312940 |
| | Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality | Q24530412 |
| | Candida colonization and subsequent infections in critically ill surgical patients | Q24535524 |
| | In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole | Q24538858 |
| | Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome | Q24811601 |
| | Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever | Q28216366 |
| | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| | Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans | Q28265703 |
| | Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome | Q28276727 |
| | Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial | Q28278518 |
| | Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. | Q30447051 |
| | International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia | Q30453797 |
| | Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. | Q33753405 |
| | Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group | Q33854646 |
| | Reproducibility of low galactomannan enzyme immunoassay index values tested in multiple laboratories | Q34042178 |
| | Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. | Q34042232 |
| | Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland | Q34194192 |
| | Epidemiology and outcome of zygomycosis: a review of 929 reported cases | Q34440240 |
| | Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. | Q34455633 |
| | Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience | Q34455699 |
| | Candidemia in Finland, 1995-1999. | Q34488253 |
| | Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program | Q37420953 |
| | Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis | Q40390928 |
| | Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. | Q40458611 |
| | Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study | Q40497134 |
| | Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia | Q40524745 |
| | Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections | Q40708990 |
| | The epidemiology of candidemia in two United States cities: results of a population-based active surveillance | Q41696774 |
| | Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial | Q43801360 |
| | Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (A | Q44505225 |
| | Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants | Q44606439 |
| | Antifungal therapy in patients with fever and neutropenia--more rational and less empirical? | Q45086607 |
| | Combination antifungal therapy for invasive aspergillosis | Q45096994 |
| | Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy | Q45172488 |
| | Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients | Q45187465 |
| | In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. | Q45200724 |
| P921 | main subject | invasive fungal infections | Q55022218 |
| P304 | page(s) | 19-27 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Infectious Diseases and Clinical Microbiology | Q15766978 |
| P1476 | title | Update on invasive fungal infections: the last two years | |
| P478 | volume | 25 | |